Report Highlights
The global market for antifungal therapeutics was valued at $10.7 billion in 2011 and is projected to reach $12.2 billion in 2016, a five-year compound annual growth rate (CAGR) of 2.7%.
SCOPE OF REPORT
This study examines human applications both marketed and in the development of antifungal technologies. In an extensive analysis, BCC examines each market segment, presents its current market status, and presents various forecasts for growth over the next five years. Other factors such as Food and Drug Administration (FDA) restrictions, government legislation, fungal resistance, and changes in consumerism such as a greater demand for OTC medications and/or natural and alternative remedies are also highlighted. Our financial and sales analysis focuses on the available figures from 2010 to 2011, with estimates for 2016, including CAGR as a percentage.
Analyst Credentials
Mary Anne Crandall is a medical research analyst and has specialized in the pharmaceuticals and medical device industry for the last 25 years. She has completed several in-depth studies on various medical topics requiring both expertise and knowledge of the industry. She is a retired nurse, has a B.S. and an M.S. in Psychology and is currently working on her Ph.D.
Related Reports
Markets for Advanced Wound Care Technologies
The total market for advanced wound care reached at $3.4 billion in 2010. It is expected to reach at $3.6 billion in 2011; it will further grow to $4.6 billion by 2016 at a compound annual growth rate (CAGR) of 4.9%.
Track the Latest Global Tariff Developments
In today's fast-paced global economy, tariffs are no longer static—they are dynamic levers shaped by geopolitical realignments, supply chain vulnerabilities, inflationary pressures, and sustainability-driven trade reforms. As governments worldwide recalibrate their trade strategies, businesses are left to navigate a maze of shifting rules, rising costs, and regulatory uncertainty.
Our analysis empowers you with real-time updates and in-depth expert analysis on all facets of global tariff activity. From new trade agreements and sanctions to abrupt tariff hikes and retaliatory duties, we monitor developments across borders, sectors, and industries—so you don't have to.
Whether it's the ongoing U.S.–China trade dynamics, the evolving EU Carbon Border Adjustment Mechanism (CBAM), or the emerging policies in India, ASEAN, and Latin America, we provide full-spectrum coverage. We also track multilateral trade negotiations, World Trade Organization (WTO) rulings, and sector-specific duty structures—ensuring you are always ahead of global trade shifts.
With our analysis, you can stay informed, identify risks, and confidently respond to tariff changes—no matter where you operate.
Ready to see what tariff means for your business?
Consult with our experts or request your custom Tariff Impact Brife today
Stay Informed, Stay Competitive
In today's interconnected and unpredictable global economy, staying ahead of tariff shifts is not just important—it's essential. BCC Research provides decision-makers with trusted, research-driven insights that turn uncertainty into opportunity.
Our in-depth market analysis and trade intelligence help you decode how tariff changes impact your specific sector—manufacturing, healthcare, technology, agriculture, or energy. We break down complex data into actionable knowledge through comprehensive reports, expert commentaries, and sector-focused forecasts.
Our analysis includes:
- Thorough breakdowns of current and proposed tariff policies and how they affect regional and global trade flows.
- Sector-specific implications, helping you understand the strategic impact on sourcing, pricing, and competitiveness.
- Forward-looking insights to support risk management, planning, and response strategies for evolving trade conditions.
With BCC Research, you gain more than just information—you gain clarity and confidence to make well-informed decisions in a volatile trade environment.
Don't let tariffs catch you off guard—let our insights guide your strategy.
Recent Reports
Therapies for Rheumatoid Arthritis: Technologies and Global Markets
The global market for rheumatoid arthritis therapies was valued at $28.5 billion in 2024 and is estimated to increase from $30.2 billion in 2025 to reach $41.1 billion by 2030, at a compound annual growth rate (CAGR) of 6.3% from 2025 through 2030.
Anti-Parkinson's Drugs: Global Markets to 2030
The global market for anti-Parkinson’s drugs is projected to grow from $6.1 billion in 2025 to reach $9.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2030.
Global Markets for Infectious Disease Treatments
The global market for infectious disease treatments is expected to grow from $72.5 billion in 2025 and is projected to reach $101 billion by the end of 2030, at a compound annual growth rate (CAGR) of 6.9% during the forecast period of 2025 to 2030.
Disease-Modifying Therapies for Alzheimer’s Disease: Global Markets
This report provides an overview of the global and regional markets for disease-modifying therapies for Alzheimer’s disease. It includes global revenue ($ million) for base year data of 2024, estimates for 2025, and CAGR forecasts through 2030.
Global Markets for Allergy Diagnostics and Treatments
The global market for allergy diagnostics and treatment is projected to grow from $67.8 billion in 2025 to $96.4 billion by the end of 2030, at a compound annual rate growth (CAGR) of 7.3% from 2025 through 2030.
Report Highlights
-
The global market for human antifungal therapeutics was valued at $9.8 billion in 2009 and is expected to increase at a compound annual growth rate (CAGR) of approximately 3.8% to reach $11.3 billion in 2014.
-
The Latin and South American region will experience the greatest compound annual growth rate (CAGR) of 8.3%, reflecting an increase in revenues from $637 million in 2009 to $949 million in 2014.
-
In North America, human antifungal therapeutics were valued at $3.9 billion in 2009 and are expected to increase at a 0.7% compound annual growth rate (CAGR) to reach $4 billion in 2014.
Report Highlights
-
The total global market for antifungal agents was worth more than $13.5 billion in 2005 and declined to just under $12.2 billion in 2006. The market will continue to dip through 2007 to $11.9 billion but will recover to more than $14.7 billion, a compound annual growth rate (CAGR) of 2.8%
-
Antifungal agents for humans held the highest share of the market through the forecast period. In 2007 they will be worth more than $11.2 billion and will reach nearly $14 billion by 2012, a CAGR of 4.5%.
-
Trends for fungal infections among animals are still a major concern as industry trends indicate. The market for animal antifungals will be worth $107 million in 2007 and will reach $110.7 million by 2012, a CAGR of 3.5%.
Report Highlights
-
The market for antifungal drugs is estimated at $5.9 billion in 2002, including both prescription and OTC products.
-
Overall, the market is projected to rise at an average annual growth rate (AAGR) of 7.9% through 2007 to $8.7 billion.
-
There are about 30 branded prescription systemic and topical antifungal agents on the market and several dozen over-the-counter branded and generic topical antifungal products.
-
Products from several entirely new categories of compounds will be introduced during the forecast period.
-
More than a dozen new prescription products are in clinical development and will contribute to the growth in this market.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More